A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
Latest Information Update: 26 Jun 2025
At a glance
- Drugs Mitotane (Primary) ; Pembrolizumab (Primary)
- Indications Adrenocortical carcinoma
- Focus Therapeutic Use
Most Recent Events
- 19 Jun 2025 Status changed from completed to discontinued.
- 15 Jul 2024 Status changed from recruiting to completed.
- 23 Mar 2023 Status changed from not yet recruiting to recruiting.